Oruka Therapeutics, Inc. held a Special Meeting of Stockholders on November 14, 2024, where stockholders approved the conversion of Series A Preferred Stock to Common Stock with 30,598,476 votes for and 6,026 against, and also approved an adjournment to solicit additional proxies with 29,294,720 votes for and 1,309,805 against.